Novo Nordisk’s Zenagamtide Isn’t Chasing Ozempic — It’s Trying to Make Tirzepatide Obsolete
Novo Nordisk's zenagamtide hit 14.6% weight loss and 89.1% A1C control in Phase 2. Here's what the ADA 2026...
Novo Nordisk
Novo Nordisk’s 20.7% Weight Loss Number Changes the GLP-1 Rulebook
Novo Nordisk's Wegovy 7.2 mg CHMP approval delivers 20.7% mean weight loss — rewriting competitive benchmarks for Eli Lilly's...
Novo Nordisk’s Weekly Insulin Isn’t Just a Dosing Upgrade — It’s a Strategic Lifeline in a GLP-1 World
FDA approval of once-weekly insulin icodec-abae (Awiqli) gives Novo Nordisk a differentiated basal insulin, but peak sales of $1.2B...
The GLP-1 Wars Are Over — The Incretin Platform Wars Have Begun
Orforglipron's 72-week Phase 3 data, SURMOUNT-5's head-to-head verdict, and Roche's oral small molecule push signal a $87B market restructuring...
Novo Nordisk’s OpenAI Deal Isn’t About Drug Discovery — It’s About Owning the Next Cost Curve
Novo Nordisk's OpenAI partnership signals a new pharma AI arms race where pipeline economics, not just science, get rebuilt...
The Efficacy Arms Race Has a New Ceiling — And Novo Nordisk Just Set It
Wegovy HD's FDA approval at 7.2 mg delivers 20.7% mean weight loss — but the real story isn't the...
Novo Nordisk’s Hims & Hers Deal Isn’t a Distribution Play — It’s a Controlled Burn of Its Own Pricing Floor
Hims & Hers posted its best weekly stock gain after announcing a deal with Novo Nordisk, and Wall Street...